Featured Editorial
-
ADC CDMO Selection For Small Biotech
8/31/2026
Manufacturing is a critical factor in ADC success. Discover how to align CDMO capabilities with molecule complexity, mitigate risks, and navigate capacity limits.
-
Evaluating The Levers Driving Productivity In Bioprocessing
8/28/2026
Experts discuss where productivity gains can be achieved and how development teams should seek to improve process performance in this recap of the Bioprocess Online Live event "The Levers And Tradeoffs That Drive Process Productivity."
-
Implementing AI Solutions In GMP While Managing Risk
8/28/2026
When using artificial intelligence in GMP settings, risk management extends far beyond validation. This discussion explores moving AI solutions out of the pilot phase.
-
Europe's ATMP Opportunity Still Requires Local Navigation
8/27/2026
European nations offer a welcoming environment for clinical-phase cell and gene therapies. Don't assume the same flexibility carries through to commercialization.
-
The Unspoken Truth About Cell Therapy Product Understanding
8/27/2026
Developers often discover important attributes after it's too late to act on them. A well-designed program asks what's needed for commercialization and works backward.
-
Overcoming Recovery Challenges In AAV Production
8/26/2026
Siren Biotechnology's SVP of vector development, Nathalie Clément, Ph.D., explains the challenge of purifying AAV capsids and the ways developers are optimizing vector recovery.
-
Enzyme Activity As A Surrogate Potency Marker In Cell Therapy
8/26/2026
When measuring cell therapy potency, biochemical assays can provide a rapid alternative to the time- and material-consuming standard of cell-based assays.
-
Implementing And Optimizing Your eQMS
8/25/2026
This article addresses everything that follows the signed contract for an eQMS: how a system is configured, validated, adopted, and maintained.
-
Choosing Analytical Technologies At The Right Stage Of Development
8/24/2026
Take a beat before investing in the latest analytical tools. Capability and sensitivity come at a cost. Depending on your phase, you might not need it just yet.
-
CDMO Selection For Small Biotech: Amit Jain On Avoiding Costly Transfers
8/20/2026
Make smarter outsourcing decisions early. Reduce the risk of costly tech transfers, evaluate capacity needs, speed development timelines, and strengthen manufacturing partnerships.